Table 3.

MINORS scale for assessing the quality of studies included in the meta-analysis

Study	A clearly stated aim	Inclusion of consecutive patients	Prospective collection of data	Endpoints appropriate to the aim of the study	Unbiased assessment of the study endpoint	Follow-up period appropriate to the aim of the study	Loss to follow up less than 5%	Prospective calculation of the study size	Total
Chen 2024	1	2	2	2	0	1	2	0	10
Su 2025	0	2	2	2	0	1	2	0	9
Li 2024	1	2	2	2	0	2	2	0	11
Zhu 2022	2	2	2	1	0	1	2	0	10
Wang 2022	2	2	2	1	0	1	2	0	10
Shen 2024	0	2	2	2	0	1	2	0	9
Zhu 2023	1	2	2	2	0	1	2	0	10
Xu 2023	0	2	2	2	0	2	2	0	10
Chang 2022	2	2	2	2	0	2	2	0	12
Wu 2024	2	2	2	2	0	1	2	0	11
Zhu 2023	2	2	2	2	0	2	2	0	12
Duong 2023	2	2	2	2	0	0	2	0	10
Qin 2025	2	2	2	2	0	2	2	0	12
Zuo 2022	2	2	2	2	0	2	2	0	12